SCHEMBL707325

SCHEMBL707325

Cc1ccc(CC(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3CC(=O)O)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 9/20 0.64
LTB4R2 Q9NPC1 3/20 0.60
MLNR O43193 2/20 0.59
REN P00797 2/20 0.51
LPAR2 Q9HBW0 1/20 0.49
CNR2 P34972 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
FFAR1 O14842 2/20 0.48
FFAR4 Q5NUL3 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709627 0.90 LPAR1 (0.61) LPAR1LTB4R2MLNRRENCNR2
SCHEMBL707323 0.89 LPAR1 (0.74) LPAR1LTB4R2MLNRLPAR2FFAR1
SCHEMBL708729 0.85 LTB4R2 (0.81) LPAR1LTB4R2
SCHEMBL709702 0.85 LPAR1 (0.60) LPAR1LTB4R2MLNRRENHDAC1
SCHEMBL706827 0.83 LPAR1 (0.63) LPAR1LTB4R2MLNRLPAR2
SCHEMBL708883 0.81 LPAR1 (0.75) LPAR1LTB4R2LPAR2
SCHEMBL704684 0.80 LPAR1 (0.85) LPAR1LPAR2FFAR1FFAR4
SCHEMBL708251 0.80 LPAR1 (0.61) LPAR1LTB4R2MLNRLPAR2
SCHEMBL708254 0.80 LPAR1 (0.59) LPAR1LTB4R2MLNRLPAR2FFAR1
SCHEMBL709379 0.79 LPAR1 (0.64) LPAR1LTB4R2MLNRLPAR2FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553075-B1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2013-08-14 EP disclosed
EP-2565178-A1 LPA Receptor Antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2013-03-06 EP disclosed
US-20120088782-A1 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-12 US disclosed
US-8124645-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2012-02-28 US disclosed
US-7820682-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-26 US disclosed
US-20100249157-A2 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-30 US disclosed
US-20080293764-A1 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. 2008-11-27 US disclosed
US-20060148830-A1 Lpa receptor antagonist ONO PHARMACEUTICAL CO., LTD. 2006-07-06 US disclosed
EP-1553075-A1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293764-A1 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LPAR1 1/4885LTB4R2 59/4885MLNR 145/4885
US-20100249157-A2 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LPAR1 1/4885LTB4R2 59/4885MLNR 145/4885
US-20120088782-A1 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LPAR1 1/4885LTB4R2 59/4885MLNR 145/4885
US-20060148830-A1 Lpa receptor antagonist LPAR1, LPAR2, LPAR4 LPAR1 1/4885LTB4R2 59/4885MLNR 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.